These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7544214)

  • 21. The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
    Chess-Williams R
    Expert Opin Pharmacother; 2002 Feb; 3(2):167-72. PubMed ID: 11829730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
    Kirby RS
    Br J Clin Pract Suppl; 1994 May; 74():23-8. PubMed ID: 7519438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and tamsulosin, an alpha1-adrenoceptor antagonist, and their synergistic effects on the urodynamic characteristics in a guinea-pig model of functional bladder outlet obstruction.
    Nagabukuro H; Hashimoto T; Iwata M; Doi T
    BJU Int; 2005 May; 95(7):1071-6. PubMed ID: 15839935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silodosin (Rapaflo) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2009 Jan; 51(1303):3-4. PubMed ID: 19122568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic therapy for prostatism.
    Lieber MM
    Mayo Clin Proc; 1998 Jun; 73(6):590-6. PubMed ID: 9621869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
    Madersbacher S; Marszalek M
    Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
    Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.
    Witjes WP; Rosier FW; de Wildt MJ; van Iersel MP; Debruyne FM; de La Rosette JJ
    J Urol; 1996 Apr; 155(4):1317-23. PubMed ID: 8632523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
    Ramsay JW; Scott GI; Whitfield HN
    Br J Urol; 1985 Dec; 57(6):657-9. PubMed ID: 2417649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased bladder apoptosis with alpha-1 adrenoceptor antagonists in benign prostatic hyperplasia.
    Erdoğru T; Gülkesen KH; Kukul E; Yalçinkaya M; Karpuzoğlu G; Baykara M
    Scand J Urol Nephrol; 2002; 36(3):188-93. PubMed ID: 12201933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
    Chapple CR
    Br J Urol; 1998 Mar; 81 Suppl 1():34-47; discussion 64-6. PubMed ID: 9589016
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pharmacological properties of naftopidil, a drug for treatment of the bladder outlet obstruction for patients with benign prostatic hyperplasia].
    Ikegaki I
    Nihon Yakurigaku Zasshi; 2000 Aug; 116(2):63-9. PubMed ID: 10976457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Kaplan SA
    J Urol; 2005 Sep; 174(3):1011. PubMed ID: 16094031
    [No Abstract]   [Full Text] [Related]  

  • 34. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Rutks I
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD002081. PubMed ID: 21901681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
    Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary results of a randomized crossover clinical trial comparing a new electromagnetic and vibrating device and alpha-blocker agents in patients affected by bladder outlet obstruction secondary to benign prostatic hyperplasia.
    Brardi S; Romano G; Cevenini G
    Arch Ital Urol Androl; 2021 Dec; 93(4):501-504. PubMed ID: 34933545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N
    J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction.
    Baldwin KC; Ginsberg PC; Harkaway RC
    Urol Int; 2001; 66(2):84-8. PubMed ID: 11223749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.